ELAVL1 and B-cell chronic lymphocytic leukemia: Inhibiting HuR can enhance apoptosis and anti-inflammatory responses in chronic lymphocytic leukemia (CLL) cells, rendering them more sensitive to chemotherapy and other treatments [39].